Adriana Scheliga
0000-0002-8808-9753
Publication & Citation Trends
Publications
5 total
Real-world analysis of patients with CLL treated with ibrutinib: a retrospective analysis of Brazilian Registry of CLL PDF
Cited by 1
OpenAlex
Fixed-duration ibrutinib-venetoclax for first-line treatment of patients with chronic lymphocytic leukemia: the REALITY-WW prospective real-world study cohort PDF
Cited by 0
OpenAlex
Diagnosis and treatment of chronic lymphocytic leukemia: 2025 recommendations of the Brazilian Group of Chronic Lymphocytic Leukemia of the Brazilian Association of Hematology and Hemotherapy (ABHH)
Cited by 2
Semantic Scholar
Real-world (RW) use of fixed-duration (FD) ibrutinib+venetoclax (Ibr+Ven) in patients (pts) with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Pooled analysis of REALITY-worldwide (WW) and REALITY-2 prospective cohort studies
Cited by 0
Semantic Scholar
How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation PDF
Cited by 37
OpenAlex
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma OA
Cited by 346
Semantic Scholar
PS1252 PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO (AUGMENT) OA
Cited by 0
Semantic Scholar
Efficacy and time to next treatment following lenalidomide/rituximab (R2) or rituximab/placebo in patients with R/R indolent NHL (AUGMENT).
Cited by 0
Semantic Scholar
Research Topics
Chronic Lymphocytic Leukemia Research
(3)
Lymphoma Diagnosis and Treatment
(2)
Phagocytosis and Immune Regulation
(2)
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
(1)
COVID-19 and healthcare impacts
(1)
Affiliations
Instituto de Oncologia do Paraná
Instituto Nacional de Câncer - INCA
Fleury S.A. (Brazil)
Sociedade Brasileira de Oncologia Clínica